Supernus Pharmaceuticals, Inc. (SUPN)
42.38
+0.20
(+0.47%)
USD |
NASDAQ |
Oct 02, 16:00
42.40
+0.02
(+0.05%)
After-Hours: 20:00
Supernus Pharmaceuticals Gross Profit Margin (Quarterly) : 72.88% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 72.88% |
| March 31, 2026 | 76.15% |
| December 31, 2025 | 77.30% |
| September 30, 2025 | 77.20% |
| June 30, 2025 | 76.94% |
| March 31, 2025 | 75.87% |
| December 31, 2024 | 74.19% |
| September 30, 2024 | 78.56% |
| June 30, 2024 | 77.05% |
| March 31, 2024 | 74.20% |
| December 31, 2023 | 74.86% |
| September 30, 2023 | 73.06% |
| June 30, 2023 | 69.17% |
| March 31, 2023 | 71.34% |
| December 31, 2022 | 73.49% |
| September 30, 2022 | 73.13% |
| June 30, 2022 | 75.29% |
| March 31, 2022 | 74.23% |
| December 31, 2021 | 81.31% |
| September 30, 2021 | 83.37% |
| June 30, 2021 | 77.59% |
| March 31, 2021 | 83.53% |
| December 31, 2020 | 81.25% |
| September 30, 2020 | 81.82% |
| June 30, 2020 | 90.98% |
| Date | Value |
|---|---|
| March 31, 2020 | 95.10% |
| December 31, 2019 | 95.91% |
| September 30, 2019 | 95.28% |
| June 30, 2019 | 96.14% |
| March 31, 2019 | 95.69% |
| December 31, 2018 | 96.39% |
| September 30, 2018 | 95.92% |
| June 30, 2018 | 96.30% |
| March 31, 2018 | 96.38% |
| December 31, 2017 | 95.30% |
| September 30, 2017 | 91.99% |
| June 30, 2017 | 94.91% |
| March 31, 2017 | 94.88% |
| December 31, 2016 | 93.95% |
| September 30, 2016 | 93.97% |
| June 30, 2016 | 94.67% |
| March 31, 2016 | 95.40% |
| December 31, 2015 | 93.60% |
| September 30, 2015 | 94.17% |
| June 30, 2015 | 95.06% |
| March 31, 2015 | 94.37% |
| December 31, 2014 | 92.59% |
| September 30, 2014 | 97.48% |
| June 30, 2014 | 94.40% |
| March 31, 2014 | 94.56% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Indivior Pharmaceuticals, Inc. | 85.42% |
| Prestige Consumer Healthcare, Inc. | 49.11% |
| Pfizer Inc. | 62.94% |
| Amphastar Pharmaceuticals, Inc. | 48.73% |
| Bristol Myers Squibb Co. | 67.95% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -10.40% |
| Return on Assets | -7.48% |
| Return on Invested Capital | -10.03% |
| Profit Margin (Quarterly) | -26.65% |
| Operating Margin (Quarterly) | -2.49% |
| Return on Net Operating Assets | -11.54% |